Related Experiment Video
Updated: Jan 23, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer
Toshiki Ito1, Kent Kanao2, Kiyoshi Takahara3
1Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Background/Aim:
Limited information is available to help physicians decide when to introduce cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC) patients. The objective of this study was to assess the optimal timing of cabazitaxel introduction.
Patients And Methods:
The clinical outcomes of 66 mCRPC patients receiving cabazitaxel following failure of docetaxel were retrospectively analyzed.
Results:
Among the parameters possibly affecting the timing of cabazitaxel introduction, only an increased prostate-specific antigen (PSA) value from the diagnosis of CRPC had a significant impact on overall survival (OS) after the introduction of cabazitaxel. Furthermore, there was a significant correlation between the increased PSA value from the diagnosis of CRPC and the baseline PSA value at cabazitaxel introduction. Multivariate analysis showed that only the baseline PSA value at cabazitaxel introduction is an independent predictor of OS.
Conclusion:
A comparatively low PSA value could be an alternative index suggesting the optimal timing for cabazitaxel introduction.
Insights
For metastatic castration-resistant prostate cancer (mCRPC), a lower prostate-specific antigen (PSA) level at the start of cabazitaxel treatment may indicate optimal timing for improved overall survival (OS). This finding aids physicians in mCRPC treatment decisions.
Area of Science:
- Oncology
- Urology
- Clinical Pharmacology
Background:
- Limited guidance exists for initiating cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) patients post-docetaxel failure.
- Optimal timing for cabazitaxel introduction remains an area requiring further clarification.
Purpose of the Study:
- To evaluate the optimal timing for introducing cabazitaxel in mCRPC patients.
- To identify predictors of overall survival (OS) following cabazitaxel initiation.
Main Methods:
- Retrospective analysis of clinical outcomes in 66 mCRPC patients treated with cabazitaxel after docetaxel failure.
- Assessment of various parameters, including prostate-specific antigen (PSA) levels, for their impact on OS.
Main Results:
- An elevated PSA value from the diagnosis of castration-resistant prostate cancer (CRPC) significantly impacted OS after cabazitaxel introduction.
- A strong correlation was observed between PSA increase from CRPC diagnosis and baseline PSA at cabazitaxel initiation.
- Multivariate analysis identified baseline PSA at cabazitaxel introduction as an independent predictor of OS.
Conclusions:
- A lower baseline PSA value at cabazitaxel introduction may serve as an indicator for optimal treatment timing.
- This finding can assist clinicians in making informed decisions regarding cabazitaxel therapy for mCRPC.
Related Concept Videos
Treatment Resistant Cancers
Resistivity
Resistance
Optimal Foraging
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Equivalent Resistance

